Claudin-4 (CLDN4): A transmembrane protein critical for tight junction formation in epithelial cells, often overexpressed in cancers. Antibodies targeting CLDN4 are under investigation for cancer therapy .
Cyclin B4 (Clb4): A yeast protein regulating microtubule dynamics during mitosis. Research on Clb4 antibodies is limited, with one study detailing its role in spindle alignment .
This article focuses on Claudin-4 Antibodies, given their therapeutic relevance and extensive documentation.
Claudin-4 is a tight junction protein overexpressed in cancers like colorectal, gastric, and bladder carcinomas. Antibodies targeting its extracellular domain disrupt tumor integrity and enhance drug penetration .
Tight Junction Disruption: Anti-CLDN4 antibodies (e.g., 4D3, xi-5D12) impair tumor cell adhesion, increasing paracellular permeability for chemotherapeutics .
Antibody-Dependent Cellular Cytotoxicity (ADCC): Some antibodies (e.g., xi-5D12) activate immune-mediated tumor cell lysis .
Synergy with Targeted Therapies: Sequential treatment with anti-CLDN4 and anti-EGFR antibodies (e.g., cetuximab) enhances efficacy in colorectal cancer models .
Immunohistochemistry (IHC): EP617 detects CLDN4 in colorectal adenocarcinoma .
Flow Cytometry: MAB4219 and FAB4219A enable surface CLDN4 detection in live cells .
Therapeutic Development: 4D3 enhances cetuximab penetration in 3D tumor spheroids .
KEGG: sce:YLR210W
STRING: 4932.YLR210W
CLB4 (Cyclin B4) is a B-type cyclin in Saccharomyces cerevisiae that plays crucial roles in cell cycle regulation, particularly in controlling astral microtubule (aMT) dynamics during cell division. Research has identified CLB4 as an APC/C Cdc20 substrate whose degradation is required for aMT stabilization in anaphase . Antibodies against CLB4 are essential tools for studying cell cycle progression, protein degradation mechanisms, and microtubule dynamics in yeast.
CLB4 antibodies target specific epitopes of the CLB4 protein that distinguish it from other B-type cyclins (Clb1, Clb2, Clb3, Clb5, and Clb6). Unlike Clb2, whose degradation is mainly dependent on the APC/C Cdh1 complex, CLB4 degradation kinetics more closely resemble those of Pds1, a known APC/C Cdc20 substrate . Properly validated CLB4 antibodies should demonstrate minimal cross-reactivity with other cyclins, making them suitable for specific detection of CLB4-related events during cell cycle progression.
CLB4 antibodies are primarily used in the following applications:
Western blotting to track CLB4 protein levels throughout the cell cycle
Immunoprecipitation to study CLB4 interactions with other proteins
Immunofluorescence to examine subcellular localization
Monitoring CLB4 degradation by the APC/C Cdc20 complex
Investigating CLB4's role in astral microtubule regulation
To effectively monitor CLB4 degradation:
Synchronize yeast cultures using hydroxyurea (HU) arrest, which arrests cells in S-phase
Release cells from arrest and collect samples at defined timepoints
Extract proteins using methods that preserve post-translational modifications
Perform western blot analysis with validated CLB4 antibodies
Compare CLB4 degradation kinetics with other known APC/C Cdc20 substrates such as Pds1
Research has shown that CLB4 protein levels remain high in cdc20 mutant cells but drop when cells enter anaphase in wild-type, cdc14 cdc5, and cdc15 cells, confirming its degradation pattern as an APC/C Cdc20 substrate .
For optimal CLB4 detection by western blot:
| Parameter | Recommendation |
|---|---|
| Sample preparation | Fresh whole cell extracts with protease/phosphatase inhibitors |
| Gel percentage | 10-12% SDS-PAGE for optimal resolution |
| Transfer conditions | Lower voltage, longer time for complete transfer |
| Blocking solution | 5% non-fat milk or BSA in TBST |
| Primary antibody | 1:1000 to 1:5000 dilution, incubate at 4°C for 12h |
| Positive control | Synchronized cells at metaphase |
| Negative control | clb4Δ strains |
Researchers have successfully used these parameters to track CLB4 levels in synchronous cell cycle experiments and in cells with altered Cdc20 expression .
Essential controls for CLB4 antibody experiments include:
Genetic controls: Include clb4Δ strains to confirm antibody specificity
Cell cycle controls: Use synchronized cells at known cell cycle stages
Related protein controls: Compare with other cyclins (e.g., Clb2) to demonstrate specificity
Loading controls: Use stable proteins unaffected by cell cycle
Epitope competition: Perform peptide competition assays to validate specificity
Studies examining CLB4 as an APC/C Cdc20 substrate utilized S-phase arrested cells with hydroxyurea as controls, along with comparisons to Pds1 and Clb2 degradation patterns .
To study APC/C Cdc20-mediated degradation of CLB4:
Generate strains with various APC/C or Cdc20 mutations (e.g., cdc20 temperature-sensitive alleles)
Arrest cells at specific cell cycle stages (e.g., S-phase with hydroxyurea)
Induce Cdc20 expression using inducible promoters (e.g., GAL-CDC20)
Monitor CLB4 levels by western blot
Compare degradation kinetics with known APC/C Cdc20 substrates
Research has demonstrated that in S-phase arrested cells, high levels of Cdc20 lead to rapid CLB4 degradation, while Clb2 remains stable, confirming CLB4 as an APC/C Cdc20 substrate .
To investigate CLB4's function in astral microtubule regulation:
Compare aMT length and stability in wild-type vs. various mutant strains
Perform immunofluorescence to co-localize CLB4 with microtubule components
Use live-cell imaging of GFP-tagged tubulin in CLB4 mutant backgrounds
Correlate CLB4 degradation timing with changes in aMT dynamics
Examine synthetic genetic interactions between CLB4 and microtubule-associated proteins
Studies have shown that deletion of CLB4 in a cdc20 background leads to abnormally stable metaphase aMTs, resembling the phenotype of esp1 cdc15 cells, which indicates CLB4's specialized role in aMT regulation compared to other cyclins .
Inconsistent results with CLB4 antibodies could be due to:
| Issue | Possible Cause | Solution |
|---|---|---|
| Variable signal intensity | Cell cycle asynchrony | Improve synchronization protocols |
| Multiple bands | Degradation products | Add complete protease inhibitor cocktail |
| Weak or no signal | Epitope masking | Try different extraction buffers |
| Background bands | Cross-reactivity | Validate with clb4Δ controls |
| Inconsistent loading | Sample preparation | Standardize protein extraction method |
Research on CLB4 degradation has demonstrated the importance of carefully synchronized cultures and proper controls when monitoring this cell cycle-regulated protein .
To validate CLB4 antibody specificity:
Perform western blots comparing wild-type and clb4Δ strains
Test reactivity against recombinant CLB4 protein
Conduct peptide competition assays
Verify expected molecular weight and cell cycle-dependent expression pattern
Check for cross-reactivity with other B-type cyclins
Researchers validating CLB4 as an APC/C Cdc20 substrate confirmed antibody specificity by observing expected degradation patterns and molecular weight, with comparative analysis against other cyclins like Clb2 .
Current research applications include:
Investigating CLB4's role in spindle assembly checkpoint signaling
Examining the relationship between CLB4 degradation and anaphase onset
Studying how CLB4-CDK activity regulates microtubule-cortex interactions
Analyzing synthetic genetic interactions between CLB4 and checkpoint components
Investigating CLB4's unique function in astral microtubule stabilization
Recent findings highlight that CLB4 has a specialized role among cyclin subunits, as its degradation by APC/C Cdc20 is specifically required for proper aMT stabilization during anaphase .
Cutting-edge approaches include:
Super-resolution microscopy to visualize CLB4 localization at microtubule plus ends
Live-cell imaging using fluorescently tagged proteins to correlate with CLB4 levels
FRAP (Fluorescence Recovery After Photobleaching) to study CLB4 dynamics
Proximity ligation assays to detect CLB4 interactions with specific proteins in situ
Correlative light and electron microscopy to examine CLB4's role in microtubule ultrastructure
These techniques have helped researchers understand how CLB4-Cdk1 controls the interaction of astral microtubule plus ends with cortical capture sites during cell division .
The timing and mechanism of CLB4 degradation show distinctive characteristics:
| Protein | Degradation Timing | Primary Degradation Pathway | Key Features |
|---|---|---|---|
| CLB4 | Early anaphase | APC/C Cdc20 | Resembles Pds1 degradation pattern |
| Pds1 | Early anaphase | APC/C Cdc20 | Canonical APC/C Cdc20 substrate |
| CLB2 | Late anaphase/telophase | Primarily APC/C Cdh1 | Partially degraded in anaphase |
| Kip1 | Metaphase/anaphase | APC/C Cdc20 | Motor protein, partial effect on aMTs |
| Acm1 | Anaphase | APC/C Cdc20 | APC/C Cdh1 inhibitor |
Research has shown that CLB4 degradation kinetics closely resemble those of Pds1, differentiating it from CLB2, which shows delayed degradation and is only partially degraded in anaphase-arrested cells .
CLB4 has a unique and specialized function among cyclin subunits:
CLB4 is specifically involved in astral microtubule stabilization
Deletion of CLB4, but not other cyclins, significantly alters aMT length and number
CLB4-Cdk1 activity regulates the interaction of astral microtubule plus ends with cortical capture sites
CLB4 degradation by APC/C Cdc20 is required for proper spindle positioning and orientation
While other cyclins may have overlapping functions, CLB4's role in aMT dynamics appears to be unique
These findings highlight that CLB4 has a specialized function that distinguishes it from other B-type cyclins in yeast cell cycle regulation .